Prevention and Treatment of Frostbite

Publication Date: July 1, 2019
Last Updated: March 14, 2022

Prevention

MAINTAINING PERIPHERAL PERFUSION

Preventive measures to ensure local tissue perfusion include: 1) maintaining adequate core temperature and body hydration; 2) minimizing the effects of known diseases, medications, and substances (including awareness and symptoms of alcohol and drug use) that might decrease perfusion; 3) covering all skin and the scalp to insulate from the cold; 4) minimizing blood flow restriction, such as occurs with constrictive clothing, footwear, or immobility; 5) ensuring adequate nutrition; and 6) using supplemental oxygen in severely hypoxic conditions (eg, >7500 m). (1 – Strong, C)
679

EXERCISE

Exercise is a specific method to maintain peripheral perfusion. Exercise enhances the level and frequency of cold-induced peripheral vasodilation. In one study, exercise resulted in cold-induced peripheral vasodilation in the toes of 58% of exercising subjects vs 28% in nonexercising subjects. Another study found increased skin temperature in the hands during exercise. However, using exercise to increase warmth can lead to exhaustion, with subsequent profound systemic heat loss should exhaustion occur. Recognizing this caveat, exercise and its associated elevation in core and peripheral temperatures can be protective in preventing frostbite. (1 – Strong, B)
However, using exercise to increase warmth can lead to exhaustion, with subsequent profound systemic heat loss should exhaustion occur.
679

PROTECTION FROM COLD

Measures should be taken to minimize exposure of tissue to cold. These measures include the following:
  1. avoiding environmental conditions that predispose to frostbite, specifically below -15°C, even with low wind speeds;
  2. protecting skin from moisture, wind, and cold;
  3. avoiding perspiration or wet extremities;
  4. increasing insulation and skin protection (eg, by adding clothing layers, changing from gloves to mitts);
  5. ensuring beneficial behavioral responses to changing environmental conditions (eg, not being under the influence of illicit drugs, alcohol, or extreme hypoxemia)
  6. using chemical hand and foot warmers and electric foot warmers to maintain peripheral warmth (note: warmers should be close to body temperature before being activated and must not be placed directly against skin or constrict flow if used within a boot);
  7. regularly checking oneself and the group for extremity numbness or pain and warming the digits and/or extremities as soon as possible if there is concern that frostbite may be developing;
  8. recognizing frostnip or superficial frostbite before it becomes more serious; and
  9. minimizing duration of cold exposure. Emollients do not protect against—and might even increase—risk of frostbite.
  10. The time that a digit or extremity can remain numb before developing frostbite is unknown; thus, digits or extremities with paresthesia should be warmed as soon as possible. An extremity at risk for frostbite (eg, numbness, poor dexterity, pale color) should be warmed with adjacent body heat from the patient or a companion, using the axilla or abdomen.
( 1 – Strong , C)
679

Field treatment and secondary prevention

REFREEZING INJURY

A decision must be made whether to thaw the tissue. If environmental conditions are such that thawed tissue could refreeze, it is safer to keep the affected part frozen until a thawed state can be maintained. Prostaglandin and thromboxane release associated with the freeze–thaw cycle causes vasoconstriction, platelet aggregation, thrombosis, and, ultimately, cellular injury. Refreezing thawed tissue further increases release of these mediators, and significant morbidity may result. One must absolutely avoid refreezing if field thawing occurs. (1 – Strong, B)
679

SPONTANEOUS OR PASSIVE THAWING

Most frostbite thaws spontaneously and should be allowed to do so if rapid rewarming (described in the following) cannot be readily achieved. Do not purposefully keep tissue below freezing temperatures because this will increase the duration that the tissue is frozen and might result in more proximal freezing and greater morbidity. If environmental and situational conditions allow for spontaneous or slow thawing, tissue should be allowed to thaw. (1 – Strong, C)
Strategies for 2 scenarios are presented:
  • Scenario 1: The frozen part has the potential for refreezing and is not actively thawed.
  • Scenario 2: The frozen part is thawed and kept warm without refreezing until evacuation is completed.
679

THERAPEUTIC OPTIONS FOR BOTH SCENARIOS

Treatment of hypothermia

No studies examine concurrent hypothermia and frostbite. Hypothermia frequently accompanies frostbite and causes peripheral vasoconstriction that impairs blood flow to the extremities. Mild hypothermia may be treated concurrently with frostbite injury. Moderate and severe hypothermia should be treated effectively before treating frostbite injury. (1 – Strong, C)
679

Hydration

Vascular stasis can result from frostbite injury. No studies have specifically examined the effect of hydration status on frostbite outcomes, but it is believed that appropriate hydration and avoidance of hypovolemia are important for frostbite recovery. Oral fluids may be given if the patient is alert, capable of purposeful swallowing, and not vomiting. If the patient is nauseated or vomiting or has an altered mental status, IV normal saline should be given to maintain normal urine output. Intravenous fluids should optimally be warmed (minimally to 37°C but preferably to 40 to 42°C with a method that has been proven to be effective in the present environmental conditions) before infusion and be infused in small (eg, 250 mL), rapid boluses because slow infusion will result in fluid cooling and even freezing as it passes through the tubing. Fluid administration should be optimized to prevent clinical dehydration. (1 – Strong, C)
679

Low molecular weight dextran

Intravenous low molecular weight dextran (LMWD) decreases blood viscosity by preventing red blood cell aggregation and formation of microthrombi and can be given in the field once it has been warmed. In some animal studies, the extent of tissue necrosis was found to be significantly less than in control subjects when LMWD was used and was more beneficial if given early. In one animal trial, tissue in the LMWD group thawed slightly more rapidly, but overall tissue loss was no different from that of control animals. Give a test dose before administration because of the low risk of anaphylaxis. This low risk of anaphylaxis should not deter administration. The slight risk of bleeding is minimal, and benefits seem to outweigh this risk; however, availability is limited in the United States. The use of LMWD has not been evaluated in combination with other treatments such as thrombolytics. LMWD should be given if the patient is not being considered for other systemic treatments, such as thrombolytic therapy. (2 – Weak, C)
679

Ibuprofen

Nonsteroidal anti-inflammatory drugs (NSAIDs) block the arachidonic acid pathway and decrease production of prostaglandins and thromboxanes. These mediators can lead to vasoconstriction, dermal ischemia, and further tissue damage. No studies have demonstrated that any particular anti-inflammatory agent or dosing is clearly related to outcome. Aspirin has been proposed as an option and is used in many parts of the world for anti-inflammatory and platelet inhibition effects. One rabbit ear model study showed 23% tissue survival with aspirin vs 0% in the control group. However, aspirin theoretically blocks production of certain prostaglandins that are beneficial to wound healing, and the authors of the rabbit ear model study recommend ibuprofen in their treatment algorithm. No studies specifically compare aspirin with ibuprofen in frostbite. Ibuprofen should be started in the field at a dose of 12 mg·kg-1 per day divided twice daily (minimum to inhibit harmful prostaglandins) to a maximum of 2400 mg·d-1 divided 4 times daily. ( 2 – Weak , C)
679

SPECIFIC RECOMMENDATIONS—SCENARIO 1

Therapeutic options for frostbite in Scenario 1 (no active thawing) include the following:

Dressings

No evidence supports applying a dressing to a frostbitten part intended to remain frozen until rewarming can safely be achieved. If this is considered, it should only be done if practical and will not interfere with mobility. Bulky, clean, and dry gauze or sterile cotton dressings should be applied to the frozen part and between the toes and fingers. ( 2 – Weak , C)
679

Ambulation and protection

If at all possible, a frozen extremity should not be used for walking, climbing, or other maneuvers until definitive care is reached. If use of the frozen extremity for mobility is considered, a risk-benefit analysis must consider the potential for further trauma and possible poorer outcome. Although it is reasonable to walk on a foot with frostbitten toes for evacuation purposes, it is inadvisable to walk on an entirely frostbitten foot because of the potential for resulting morbidity. This risk is theoretical and based on the panel’s opinion. Mills described frostbite patients who ambulated on frozen extremities for days and sustained no or limited amputation. If using a frozen extremity for locomotion or evacuation is unavoidable, the extremity should be padded, splinted, and kept as immobile as possible to minimize additional trauma. ( 2 – Weak , C)
679

Rapid field rewarming of frostbite

Field rewarming by warm water bath immersion can and should be performed if the proper resources are available and definitive care is more than 2 h distant. Other heat sources (eg, fire, space heater, oven, heated rocks) should be avoided because of the risk of thermal burn injury. Rapid rewarming by water bath has been found to result in better outcomes than slow rewarming. Field rewarming should only be undertaken if the frozen part can be kept thawed and warm until the victim arrives at definitive care. Water should be heated to 37 to 39°C (98.6 to 102.2°F), using a thermometer to maintain this range. If a thermometer is not available, a safe water temperature can be determined by placing a caregiver’s uninjured hand in the water for at least 30 s to confirm that the water temperature is tolerable and will not cause burn injury. Circulation of water around the frozen tissue will help maintain correct temperature. Because the water may cool quickly after the rewarming process is started, the water should be continuously and carefully warmed to the target temperature. If the frozen part is being rewarmed in a pot, skin should not press against the bottom or sides. Rewarming is complete when the involved part takes on a red or purple appearance and becomes soft and pliable to the touch. This is usually accomplished in approximately 30 min, but the time is variable depending on the extent and depth of injury. The affected tissues should be allowed to air dry or be gently dried with a blotting technique (not rubbing) to minimize further damage. Under appropriate circumstances, this method of field rewarming is the first definitive step in frostbite treatment. (1 – Strong, B)
679

Antiseptic solution

Most injuries do not become infected, but adding an antiseptic solution (eg, povidone-iodine, chlorhexidine) to the rewarming water has theoretical benefits of reducing skin bacteria. Evidence for this practice does not exist for frostbite care, however. Adding an antiseptic solution to the water while rewarming is unlikely to be harmful and might reduce the risk for cellulitis if severe edema is present in the affected extremity. (2 – Weak, C)
679

Pain control

During rewarming, pain medication (eg, NSAIDs or an opiate analgesic) should be given to control symptoms as dictated by individual patient situation. (1 – Strong, C)
679

Spontaneous or passive thawing

According to the foregoing guidelines, rapid rewarming is strongly recommended. If field rewarming is not possible, spontaneous or slow thawing should be allowed. Slow rewarming is accomplished by moving to a warmer location (eg, tent or hut) and warming with adjacent body heat from the patient or a caregiver, as previously described. The expert panel agrees that slow thawing is a reasonable course of action to initiate the rewarming process if it is the only means available. (1 – Strong, C)
679

Debridement of blisters

Debridement of blisters should not be routinely performed in the field. If a clear, fluid-filled blister is tense and at high risk for rupture during evacuation, blister aspiration and application of a dry gauze dressing should be performed in the field to minimize infection risk. Hemorrhagic bullae should not be aspirated or debrided in the field. These recommendations are common practice but lack evidence beyond case series. ( 2 – Weak , C)
679

Topical aloe vera

Aloe vera ointment has been shown in an observational study and an animal model to improve frostbite outcome by reducing prostaglandin and thromboxane formation. Topical agents do not penetrate far into tissues, however, so aloe vera is theoretically only beneficial for superficially injured areas. The study supporting the benefit of aloe vera examined its application on unroofed blebs where it would be able to penetrate underlying tissue. Topical aloe vera should be applied to thawed tissue before application of dressings. ( 2 – Weak , C)
679

Dressings

Bulky, dry gauze dressings should be applied to the thawed parts for protection and wound care. Substantial edema should be anticipated, so circumferential dressings should be wrapped loosely to allow for swelling without placing pressure on the underlying tissue. ( 1 – Strong , C)
679

Ambulation and protection

A risk-benefit analysis must consider the potential for further trauma and, ultimately, potentially higher morbidity if a thawed part is used for ambulation. For example, it might be reasonable to walk on a foot with thawed toes for evacuation purposes, but it is inadvisable to walk on a recently thawed frostbitten foot because of the potential resulting morbidity. Very little evidence is available to guide recommendations. In one study, mobilization within 72 h after thawing did not affect tissue loss, complications, or hospital length of stay. After the rewarming process, swelling should be anticipated. If passive thawing has occurred, boots (or inner boots) may need to be worn continuously to compress swelling. Boots that were removed for active rewarming may not be able to be re-donned if tissue swelling has occurred during the warming process. The panel’s clinical experience supports the concept that a recently thawed extremity should ideally not be used for walking, climbing, or other maneuvers and should be protected to prevent further trauma. (2 – Weak, C)
679

Elevation of extremity

If possible, the thawed extremity should be elevated above the level of the heart, which might decrease formation of dependent edema. (1 – Strong, C)
679

Oxygen

Recovery of thawed tissue partly depends on the level of tissue oxygenation in the postfreezing period. One small study that measured hand temperature at normobaric hypoxia found decreased skin temperatures with decreasing FIO2. However, hyperoxia has been found to cause vasoconstriction in the extremities; therefore, oxygen should not be applied routinely to patients who are not hypoxic. Although evidence is lacking to support use of supplemental oxygen for frostbite, oxygen may be delivered by face mask or nasal cannula if the patient is hypoxic (oxygen saturation <88%) or at high altitude above 4000 m. (2 – Weak, C)
679

Immediate medical therapy—hospital (or high-level field clinic)

Once the patient reaches the hospital or field clinic, a number of treatments should be initiated. After reaching the hospital or field clinic, potential therapeutic options for frostbite include the following:

TREATMENT OF HYPOTHERMIA

Similar recommendations apply to hospital or field clinic treatment of hypothermia before frostbite treatment (see previous). (1 – Strong, C)
679

Hydration

Similar recommendations apply in the hospital or field clinic regarding hydration (see previous). ( 1 – Strong , C)
679

LOW MOLECULAR WEIGHT DEXTRAN

Similar recommendations apply in the hospital or field clinic regarding LMWD (see previous). ( 2 – Weak , C)
679

RAPID REWARMING OF FROZEN TISSUES

Frozen tissue should be assessed to determine whether spontaneous thawing has occurred. If tissue is completely thawed, further rewarming will not be beneficial. Rapid rewarming should be undertaken according to the field protocol described previously if the tissue remains partially or completely frozen. (1 – Strong, B)
679

MANAGEMENT OF BLISTERS

Clear or cloudy blisters contain prostaglandins and thromboxanes that may damage underlying tissue. Hemorrhagic blisters are thought to signify deeper tissue damage extending into the dermal vascular plexus. Common practice is to drain clear blisters (eg, by needle aspiration) while leaving hemorrhagic blisters intact. Although this approach to frostbite blister management is recommended by many authorities, comparative studies have not been performed and data are insufficient to make absolute recommendations. Some authors argue that unroofing blisters might lead to the desiccation of exposed tissue and that blisters should only be removed if they are tense, likely to break or be infected, or interfere with the patient’s range of motion. In a remote field situation, draining or unroofing blisters may not be under control of the provider. Blisters most often will have been broken by the patient’s boots. In this case, the most important treatment is applying aloe vera and a sterile dressing to the unroofed blister. Debridement or aspiration of clear, cloudy, or tense blisters is at the provider’s discretion, with consideration of patient circumstances, until better evidence becomes available. (2 – Weak, C)
679

TOPICAL ALOE VERA

Topical aloe vera cream or gel should be applied to the thawed tissue before application of dressings. Aloe vera is reapplied at each dressing change or every 6 h. (2 – Weak, C)
679

SYSTEMIC ANTIBIOTICS

Frostbite is not an inherently infection-prone injury. Therefore, antibiotic administration specifically for preventing infection during or after frostbite injury is not supported by evidence. Some authorities reserve antibiotics for situations when edema occurs after thawing because of the notion that edema increases skin susceptibility to infection by gram-positive bacteria. However, this practice is not based on evidence. Systemic antibiotics, either oral or parenteral, should be administered to patients with significant trauma, other potential infectious sources, or signs and symptoms of cellulitis or sepsis. (1 – Strong, C)
679

TETANUS PROPHYLAXIS

Tetanus prophylaxis should be administered according to standard guidelines. (1 – Strong, C)
679

IBUPROFEN

If NSAIDs have not been initiated in the field, ibuprofen should be administered at a dose of 12 mg·kg-1 divided twice daily (to inhibit harmful prostaglandins but remain less injurious to the gastrointestinal system) until the frostbite wound is healed or surgical management occurs (typically for 4 to 6 wk). (2 – Weak, C)
679

THROMBOLYTIC THERAPY

The goal of thrombolytic therapy in frostbite injury is to lyse and clear microvascular thromboses. For deep frostbite injury with potential significant morbidity, angiography and use of either IV or intra-arterial tissue plasminogen activator (tPA) within 24 h of thawing may salvage some or all tissue at risk. A retrospective, single-center review by Bruen et al. demonstrated reduction in digital amputation rates from 41% in those patients who did not receive tPA to 10% in patients receiving tPA within 24 h of injury. The 20-y series presented by the Regions Hospital group found that two-thirds of patients who received intra-arterial tPA responded well and that amputation rate correlated closely with angiographic findings. The Massachusetts General Hospital group has proposed a screening and treatment tool for thrombolytic management of frostbite based on a case report and their evaluation of the Utah and Minneapolis experiences. Twomey et al from Hennepin County Medical Center have developed a specific protocol based on a small group of good outcomes with intravenous tPA. Further study is needed to compare intra-arterial vs IV tPA on tissue salvage and functional outcome. Animal studies demonstrate benefit from thrombolytics.When considering using a thrombolytic, a risk-benefit analysis should be performed. Only deep injuries with potential for significant morbidity (eg, extending into the proximal interphalangeal joints of digits) should be considered for thrombolytic therapy. Potential risks of tPA include systemic and catheter site bleeding, compartment syndrome, and failure to salvage tissue. The long-term, functional consequences of digit salvage using tPA have not been fully evaluated.
Thrombolytic treatment should be undertaken in a facility familiar with the technique and with intensive care monitoring capabilities. If a frostbite patient is being cared for in a remote area, transfer to a facility with tPA administration and monitoring capabilities should be considered if tPA can be started within 24 h of tissue thawing. Time to thrombolysis appears to be very important, with best outcomes within 12 h and ideally as soon as possible. Recent work from Hennepin County has found that each hour of delay of thrombolytic therapy results in a 28% decrease in salvage. Rare use of tPA in the field has shown variable success and should only be undertaken with extreme caution because bleeding complications may be impossible to detect and treat. If other treatment options are limited or unavailable, tPA should be considered for field treatment only of severe frostbite extending to the proximal interphalangeal joint or more proximally (eg, Cauchy classification grade 3 to 5).

Method of administration

Dosing is typically a 3 mg bolus (30 mL of 0.1 mg·mL-1 solution) followed by infusion of 1 mg·mL-1 (10 mL·h-1) until specialists (eg, vascular, burn, radiology) recommend discontinuation. Heparin is administered concurrently: 500 units·h-1.Intra-arterial angiography or IV pyrophosphate scanning should be used to evaluate the initial injury and monitor progress after tPA administration as directed by local protocol and resources. As of the end of 2018, the following have been published on tPA use in frostbite: 1 randomized controlled prospective trial (tPA plus iloprost, 16 patients), 3 retrospective cohort studies (59 patients), 8 retrospective case series (130 patients), and 3 case reports. Although further studies are needed to determine the absolute efficacy of tPA for frostbite injury and to compare intra-arterial tPA to IV prostacyclin, we recommend IV or intra-arterial tPA within 24 h of injury as a reasonable choice in an environment with appropriate monitoring capabilities.
(1 – Strong, C)
679

IMAGING

In patients with delayed presentation (4-24 h from the time of the frostbite thawing), noninvasive imaging with technetium pyrophosphate or magnetic resonance angiography can be used at an early stage to predict the likely levels of tissue viability for amputation. Cauchy et al. described the combination of a clinical scoring system and technetium scanning to successfully predict subsequent level of amputation on day 2 after frostbite rewarming. Single photon emission computed tomography (CT)/CT combines the anatomic precision of CT with the functional vascular information obtained from multiphase bone scintigraphy. Kraft et al used single photon emission CT/CT for 7 patients with frostbite and found it improved surgical planning for deep frostbite injuries by enabling early and precise anatomic localization of nonviable tissues. If available, appropriate imaging should be used to assess tissue viability and guide timing and extent of amputation.
If available, appropriate imaging should be used to assess tissue viability and guide timing and extent of amputation. (1 – Strong, C)
Other potential useful imaging techniques include Doppler ultrasound; triple phase technitium; indocyanine green microangiography; and thermal imaging. Although some of these techniques show potential, further studies are required to determine their exact role.
679

ILOPROST

Iloprost, a prostacyclin (PGI2) analogue, is a potent vasodilator that also inhibits platelet aggregation, down-regulates lymphocyte adhesion to endothelial cells, and may have fibrinolytic activity. Intravenous iloprost was first used for treatment of frostbite by Groechenig in 1994, in 5 patients with second- and third-degree frostbite. He infused iloprost daily, starting at 0.5 ng·kg-1 and increasing to 2.0 ng·kg-1 total dose over 3 d, and then continued for between 14 and 42 d. Recovery without amputation was achieved in all patients.
A randomized trial by Cauchy et al assessed the efficacy of aspirin plus: 1) buflomedil, an alpha-blocker vasodilator; 2) iloprost; or 3) intravenous tPA plus iloprost. Forty-seven patients with severe frostbite, with 407 digits at risk, were randomly assigned to 8 d of treatment with the 3 different regimens. Iloprost alone (0% amputation rate) was found superior to tPA plus iloprost (19%) and buflomedil (60%) groups. A limitation of this study was that ischemia was not documented with angiography or technetium scanning before treatment; groups were randomized according to clinical severity.
A Canadian study documented full recovery of grade 3 frostbite when iloprost was started within 48 h of injury in 2 long distance runners. In a Finnish study, iloprost was partially beneficial with digit salvage rate of 78% in 4 persons: 2 with contraindication for tPA, 1 with failed tPA therapy, and 1 with vasospasm without thrombosis on angiography. One patient with minimal response to tPA had complete reperfusion with iloprost.
Despite the limitations of these initial studies, iloprost has shown consistently favorable effects. Extending the treatment window, Pandey et al. reported good results with iloprost therapy up to 72 h after injury. In 5 Himalayan climbers with 34 digits at risk, 5 d of daily iloprost infusion produced excellent outcomes in 4 of 5 patients. Treatment delayed beyond 72 h has not been beneficial except in 1 patient. No serious side effects have been noted in these studies.
Intravenous iloprost should be considered first-line therapy for grade 3 and 4 frostbite <72 h after injury, when tPA is contraindicated, and in austere environments where tPA infusion is considered risky or evacuation to a treatment facility will be delayed. Field use of both iloprost and IV tPA has been advocated to reduce delay in treatment for mountaineers who will invariably take >48 h for evacuation to a hospital. In these situations, iloprost may be the safer alternative. The IV form of iloprost is not approved by the US Food and Drug Administration, however. Consider iloprost for deep frostbite to or proximal to the proximal interphalangeal joint; within 48 h after injury, especially if angiography is not available; or with contraindications to thrombolysis. Expedition physicians should consider adding iloprost to their medical armamentarium, especially if it can be safely sourced and when treatment is occurring outside of the United States. (1 – Strong, B)

Method of administration

Iloprost dosage is given IV via controlled infusion or syringe pump. Iloprost is mixed with normal saline or dextrose in water. On days 1 through 3, start at an initial rate of 0.5 ng·kg-1·min-1, then gradually increase by 0.5 ng·kg-1·min-1 at 30-min intervals to a maximum dose of 2.0 ng·kg-1·min-1. If intolerable side effects (nausea, headache, flushing) emerge or blood pressure or heart rate are outside normal limits, reduce the rate by 0.5 ng·kg-1·min-1 until side effects are tolerable or vital signs normalize. Mild and tolerable side effects can be treated symptomatically, whereas hypotension or severe symptoms require dose reduction. Continue the highest dose achieved or a maximum of 2.0 ng·kg-1·min-1 for 6 h total. For days 4 through 5, start directly at the highest/optimum rate or a maximum of 2.0 ng·kg-1·min-1 for 6 h daily. Some protocols recommend up to 8 d of treatment; the first dose is considered the most important.
679

HEPARIN

No evidence supports use of low molecular weight heparin or unfractionated heparin for initial management of frostbite in the field or hospital, although climbers and practitioners in many regions use these medications. Evidence supports use of heparin as adjunctive therapy in tPA protocols, as described previously. Heparin has been used in conjunction with iloprost as well; the 5 patients in the 1994 Groechenig iloprost study,
the 1 Israeli traveler with excellent outcome in the Kathmandu study, and 4 patients in the Finnish study were treated with low molecular weight heparin (enoxaparin) in addition to iloprost. Whether low molecular weight heparin offers additional benefit when combined with iloprost requires further investigation; currently data are insufficient for a recommendation on this combination. (, U)
679

OTHER VASODILATOR THERAPY

Certain vasodilators have the potential to improve outcomes and can be used with minimal risk. However, as discussed earlier, data demonstrating benefit are limited. Iloprost is the only vasodilator with reasonable scientific evidence supporting its use. (, U)
679

Other post-thaw medical therapy

HYDROTHERAPY

Daily or twice-daily hydrotherapy at 37 to 39°C (98.6 to 102.2°F) has been recommended in the post-thaw period. Hydrotherapy theoretically increases circulation, removes superficial bacteria, and debrides devitalized tissue. No trials support improved outcomes, but the practice has few negative consequences and has the potential to benefit recovery. Data are insufficient to recommend specific temperature, timing, or duration of therapy. (1 – Strong, C)
679

HYPERBARIC OXYGEN THERAPY

Many types of nonfrostbite wounds show accelerated or more complete healing as a result of increased tissue oxygenation from hyperbaric oxygen therapy (HBOT). Because oxygen under pressure increases oxygen tension in the blood, HBOT is typically effective only if blood supply to distal tissues is competent and, therefore, may not be successful in frostbite. However, HBOT may have other effects such as making erythrocytes more malleable and decreasing bacterial load. Despite anecdotal success in extremely limited case series controlled studies have not been conducted. The time, expense, and availability of HBOT also limit its use. At this time, data are insufficient to recommend HBOT for frostbite treatment. (, U)
679

SYMPATHECTOMY

Because blood flow is partly determined by sympathetic tone, chemical or surgical sympathectomy has been proposed in the immediate postexposure phase to reduce tissue loss. In a rat lower limb model, early surgical denervation (within 24 h of exposure) reduced tissue loss but had no effect if performed after 24 h. In a rabbit ear model, procaine-induced sympathectomy had no demonstrable beneficial effect. Frostbite patients often experience long-term delayed symptoms, such as pain, paresthesia, and numbness. Chemical or surgical sympathectomy to treat these symptoms has been performed with variable results. In some studies, surgical sympathectomy has been found to reduce duration of pain and expedite demarcation of tissue necrosis. However, it has not been found to reduce the ultimate extent of tissue loss. Acute treatment success with IV guanethidine has been reported but was not beneficial in another case report. Sympathectomy may have a role in preventing certain long-term sequelae of frostbite such as pain (putatively caused by vasospasm), paresthesia, and hyperhidrosis. Despite many years of study, the data on surgical sympathectomy are limited and conflicting; therefore, a recommendation for their use cannot be made. (, U)
679

HOSPITALIZATION

Hospital admission and discharge are determined on an individual basis. Factors should include severity of the injury, coexisting injuries, comorbidities, and need for hospital-based interventions (tPA, vasodilators, surgery) or supportive therapy, as well as ease of access to appropriate community medical and nursing support. Significant swelling should prompt evaluation for compartment syndrome and admission for observation. Patients with superficial frostbite can usually be managed as outpatients or with brief inpatient stays followed by wound care instructions. Initially, deep frostbite should be managed in an inpatient setting. (1 – Strong, C)
679

FASCIOTOMY

Thawing results in reperfusion of ischemic tissue and, in turn, sometimes results in elevated pressures within closed soft-tissue compartments. Compartment syndrome clinically manifests as tense, painful distention with reduced movement and sensation. Urgent attention is necessary to evaluate compartment pressures. If elevated compartment pressures are present, prompt surgical decompression is indicated for limb salvage. (1 – Strong, C)
679

SURGICAL TREATMENT OR AMPUTATION

After frostbite occurs, complete demarcation of tissue necrosis may take 1 to 3 mo. Angiography, technetium-99 bone scan, or magnetic resonance imaging may be used to assist determination of surgical margins in conjunction with clinical findings. If the patient exhibits signs and symptoms of sepsis attributed to infected frostbitten tissue, amputation should be performed expeditiously. Otherwise, amputation should be delayed until definitive demarcation occurs. The affected limb is often insensate. Therefore, an approach that addresses footwear and orthotics is essential to provide optimal function. Our experience has found that early involvement of a multidisciplinary rehabilitation team produces better long-term functional results. Telemedicine or electronic consultation with a surgical frostbite expert to guide local surgeons should be considered when no local expert is available. Because significant morbidity may result from unnecessary or premature surgical intervention, a surgeon with experience evaluating and treating frostbite should assess the need for and the timing of any amputation. ( 1 – Strong , C)
679

Recommendation Grading

Disclaimer

Overview

Title

Prevention and Treatment of Frostbite

Authoring Organization

Publication Month/Year

July 1, 2019

Last Updated Month/Year

April 13, 2023

Supplemental Implementation Tools

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Inclusion Criteria

Female, Male, Adolescent, Adult, Child, Older adult

Health Care Settings

Ambulatory, Hospital, Medical transportation

Intended Users

Paramedic emt, athletics coaching, nurse, nurse practitioner, physician, physician assistant

Scope

Prevention, Management, Treatment

Diseases/Conditions (MeSH)

D007035 - Hypothermia, D005627 - Frostbite

Keywords

rewarming, Frostbite, hypothermia, thrombolysis, iloprost